Safety of a short hydration method for cisplatin administration in comparison with a conventional method--a retrospective study

Objective

Cisplatin is administered in combination with massive hydration to avoid renal toxicity, making its administration difficult in an outpatient setting. Although a short hydration protocol for cisplatin has been recently developed, its safety is not fully understood.

Methods

Consecutive patients with lung or other cancer and an Eastern Cooperative Oncology Group performance status of 0–2 who were receiving chemotherapy containing cisplatin at a dose of ≥60 mg/m² in a single administration were evaluated. Seventy-four patients were treated with a short hydration protocol consisting of 1750–2250 ml of hydration with mannitol and magnesium supplementation over a period of 3.75–4.75 h on Day 1. Sixty-nine patients were treated with a conventional hydration protocol consisting of 2100–2600 ml of hydration over 6.5–7.5 h on Day 1 with pre- and post-hydration on Days 0, 2 and 3. Toxicity was then compared between the two groups.

Results

An elevated serum creatinine level ≥grade 1 was significantly less frequent in the group receiving the short hydration protocol than in the group receiving conventional hydration. Other toxicities were similar between the two groups. Consequently, the completion rate for the planned treatment in the short hydration group (73.0%, 54/74) was significantly higher than that in the conventional hydration group (53.6%, 37/69).

Conclusions

Short hydration is safe, making cisplatin-containing chemotherapy easier to perform.

from Cancer via ola Kala on Inoreader http://ift.tt/1Skh382
via IFTTT